Revolution Medicines News

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TipRanksMay 14 07:56 ET

Buy Rating on Revolution Medicines With a $44 Target Amid Strong Financials and Upcoming Clinical Catalysts

TipRanksMay 13 06:27 ET

Revolution Medicines Analyst Ratings

BenzingaMay 13 06:32 ET

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)

TipRanksMay 10 01:20 ET

Revolution Medicines (RVMD) Receives a Buy From Piper Sandler

TipRanksMay 9 06:54 ET

Revolution Medicines Analyst Ratings

BenzingaMay 9 06:45 ET

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Revolution Medicines (RVMD) and Personalis (PSNL)

TipRanksMay 9 06:40 ET

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Revolution Medicines (RVMD)

TipRanksApr 19 07:30 ET

Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)

TipRanksApr 12 07:47 ET

Revolution Medicines Receives Buy Rating Amid Promising Cancer Treatment Data and Expanded Market Opportunities

TipRanksApr 12 06:26 ET

Revolution Medicines Analyst Ratings

BenzingaApr 12 06:14 ET

Revolution Medicines Analyst Ratings

BenzingaApr 10 13:16 ET

Revolution Medicines Analyst Ratings

BenzingaApr 8 07:06 ET

Revolution Medicines' Robust Cancer Drug Pipeline Justifies Buy Rating

TipRanksApr 8 06:35 ET

Revolution Medicines Analyst Ratings

BenzingaMar 11 06:00 ET

Buy Rating on Revolution Medicines Amid Promising RMC-6236 Trials for Multiple Cancer Treatments

TipRanksMar 11 05:05 ET

Revolution Medicines Analyst Ratings

BenzingaMar 8 06:37 ET

Revolution Medicines (RVMD) Receives a Buy From TD Cowen

TipRanksMar 7 07:15 ET

Buy Rating Affirmed for Revolution Medicines: Advancing RAS Inhibitors and Strong Financial Outlook

TipRanksFeb 27 23:36 ET

Revolution Medicines Analyst Ratings

BenzingaFeb 27 08:51 ET